# The Whitehall-Robins Report

June 2006 - Volume 15. Number 2

# **Nutrition, Aging and Cognitive Function**

SJPM Eussen MSC, O van de Rest, MSc, M Manders, MSC, CPGM de Groot, Msc, PhD. Wageningen University, Human Nutrition, The Netherlands

The aging population is growing and the risk for malnutrition and impaired cognitive functioning increases with advancing age. In the past few decades, it has become clear that many constituents of the diet, from macronutrients to micronutrients, influence brain function. Such influence on brain function in turn has an effect on mental health and performance, and subsequently on behaviour, social activities, and independence, especially in elderly people. Thus, a vicious cycle with more nutritional deficiencies and more cognitive problems is likely to develop. Cognitive decline and impaired mental well-being are strong predictors for dementia and depression, respectively. Since no curative approaches for these diseases in old age are currently available there is a need for early interventions in order to prevent these conditions from developing. Typically, preventive strategies focus on modifiable factors, including the diet. So far most of the available evidence comes from epidemiological studies. For example, cross-sectional studies have shown that low blood levels of certain nutrients such as folate, cobalamin and omega-3 fatty acids are associated with impaired cognitive functioning in elderly persons<sup>1-4</sup>. Moreover, prospective studies reveal that persons with suboptimal nutritional status might be at a higher risk for development of cognitive impairment<sup>5-7</sup>. To confirm causality, these findings need to be invesiged in clinical trials.

According to a recent systemic review<sup>8</sup> of available clinical trials, nutritional supplements may indeed improve the cognitive function of elderly persons. However, additional well designed trials are needed to identify what components of the diet are critical for cognitive function. Although a variety of dietary factors are believed to be vital in the maintenance of mental health, this review focuses on dietary factors which have been the focus of recent research: namely the B-vitamins, Omega -3 fatty acids and multivitamin/mineral supplements.

### **B**-vitamins

Cobalamin (vitamin B12) deficiency is common in elderly people and results from either the inability to release cobalamin from food proteins (food malabsorption) or intestinal malabsorption, or inadequate intake<sup>9-11</sup>. Cobalamin is involved in the one-carbon metabolism where it plays a role in the transfer of methyl groups and methylation reactions that are important for the synthesis and metabolism of neurotransmitters and phospholipids in the central nervous system<sup>12</sup>. Moreover, cobalamin is also required for nucleic acid synthesis and haematopoiesis<sup>11</sup>, and the metabolism of fatty acids and amino acids in the mitochondrial citric acid cycle<sup>13</sup>. In addition to causing anaemia, cobalamin deficiency has been linked with a variety of neuropsychiatric symptoms, such as neuropathy, myelopathy, dementia, depression, memory impairment, and cerebrovascular diseases<sup>14,15</sup>. While prolonged cobalamin deficiency may eventually result in irreversible neurological damage and cognitive impairment 16,17, early stages of cobalamin deficiency-detected by increased concentrations of plasma total homocysteine (tHcy) and methylmalonic acid (MMA)<sup>15</sup> and decreased concentrations of holotranscobalamin (holoTC)18 - may result in milder forms of cognitive impairment in the absence of anaemia<sup>19,20</sup>.

Several cross-sectional and prospective studies in both healthy and cognitively impaired elderly people have reported associations between impaired cobalamin status and cognitive performance<sup>3,21,22</sup>. So far, several intervention studies of cobalamin supplementation and cognitive performance have been performed <sup>17,23-33</sup>, of which only three were randomized placebo controlled <sup>30-32</sup>. According to a recent review of published trials, evidence of efficacy of cobalamin in improving the cognitive function of people with dementia and low serum B12 levels is inconclusive<sup>22</sup>. The main reasons for this conclusion are; the short duration of these studies, different inclusion criteria with respect

to cognitive status and cobalamin status, different doses and administration routes of cobalamin supplements, and use of global instead of sensitive neuropsychological tests to assess cognitive function. Recent trials so far lead to similar conclusions<sup>32</sup> for cobalamin supplementation or for cobalamin and folic acid<sup>34</sup> supplementation. Unfortunately none of these studies goes beyond duration of six months, hence, not addressing the potential for beneficial effects of longer term supplementation.

With cobalamin, folate is also one of the factors involved in methylation processes that are essential for the maintenance of normal brain function. Folate acts as a donor of methyl groups in a reaction catalysed by the enzyme methionine synthase to produce methylcobalamin needed for methylation of homocysteine to methionine. Folate deficiency therefore leads to an increase in blood and intracellular levels of homocysteine. Previous studies have reported an inverse association between plasma total homocysteine levels and simultaneously assessed cognitive function<sup>2,35-38</sup>. Noteworthy are findings from a prospective study including 1,092 subjects without dementia. After a median follow-up of 8 years an increased plasma homocysteine level turned out to be a strong, independent risk factor for the development of dementia and Alzheimer's disease<sup>39</sup>. Of particular interest are also findings from the Rotterdam Scan Study, which demonstrated an association between homocysteine levels, the risk of silent brain infarcts<sup>40</sup> and cognitive decline<sup>41</sup>. Though a Cochrane review of all available clinical trials suggests that folate supplementation has no effect on cognitive function in later life<sup>42</sup>, a recent Dutch trial including 818 individuals aged 50-70 years old, is the first to demonstrate that folic acid may slow down cognitive decline (manuscript submitted for publication and Presented at the International Conference on the Prevention of Dementia, Alzheimer Association, Washington DC, 2005). This study underpins the importance

of the longer study duration, as subjects complied for a period of three years to the use of an additional 800 micrograms of folic acid per day.

# **Omega-3 Fatty Acids**

The idea that long-chain omega-3 fatty acids play a role in human health has been investigated for several years. The prominence of n-3 fatty acids in the central nervous system is suggestive for their role in mental health and brain function. The dry weight of the brain constitutes of 56% lipids, and a large portion of these lipids consist of polyunsaturated fatty acids, in particular docosahexaenoic acid (DHA). DHA is a major structural component of neuronal membrane phospholipids, whereas there is only a small amount of eicosapentaenoic acid (EPA) in neural tissue, which plays an important role in nerve and signal transmission. It is therefore to be expected that they are qualitatively and quantitatively very important in brain function. Moreover, the brain fatty acid profile appears to be sensitive to dietary modifications. If omega-3 fatty acids in the diet affect the fatty acid composition of the human brain, it is possible that this consequently influences brain function.

Dietary sources for Omega-3 fatty acids are vegetable oils (containing  $\alpha$ -linolenic acid [ALA]) and foods from marine origin, in particular fatty fish (containing EPA and DHA). EPA and DHA may also be synthesized through elongation and desaturation of ALA from vegetable sources, but the efficiency of this conversion is limited in humans. It is estimated that only 5-15 % of ALA is ultimately converted to DHA<sup>43</sup>. Evidence for a role of EPA-DHA in mental processes in older ages is mostly emerging from observational 44,45 and epidemiological studies<sup>46-49</sup>. A populationbased study showed that a decreased level of EPA-DHA in cell membranes appeared to be associated with cognitive decline in elderly people<sup>50</sup>. Furthermore, an inverse relationship between fish consumption and the risk of dementia was observed in both the Rotterdam

and the Zutphen Elderly studies<sup>51</sup> and in the Rotterdam Study plasma fatty acid composition was related to depression, not secondary to inflammation, atherosclerosis or other confounders<sup>52</sup>. Taken together the current evidence strongly suggests that EPA-DHA is beneficial for mental health, but again there is a need for well designed intervention studies. No such studies have been found so far in view of a scheduled Cochrane review entitled 'Omega 3 fatty acid for the prevention of dementia'<sup>53</sup>. However, it is envisaged that within the next few years, several studies will be concluded.

## **Multivitamin/mineral Supplements**

Undernutrition is a continuing source of concern among the elderly (Manders et al, submitted). Several systematic reviews in older people 54-56 suggest that nutritional supplementation has beneficial effects on nutritional and mortality outcomes. None of these reviews could reveal an effect of nutritional supplementation on functional outcomes. This has mostly been ascribed to methodological defects in the reviewed studies. A recent meta-analysis suggests that any beneficial effect would be limited to hospitalized and institutionalized elderly patients<sup>57</sup>. Providing supplements to well nourished subjects would not be beneficial. So far most studies in institutionalized elderly could not show an effect of multivitamin/mineral supplementation on physical functioning probably due to a variety of reasons: e.g. the period of intervention might have been too short 58-60 or to the small number of participants in these studies<sup>61,62</sup>. However, two Dutch trials in institutionalized elderly people who received a nutrient dense drink did show a statistically significant and clinically relevant effect on cognitive performance in particular elderly people with low BMI<sup>63</sup>. Therefore, complete supplements may offer more to undernourished elderly people than just improvement of their nutritional status.

#### Conclusion

The evidence from epidemiological studies is strongly suggestive of a link between diet and cognitive function in older people. Some proof of the effectiveness of supplementation is emerging. So far the evidence is limited due to methodological challenges in establishing a causal effect between diet and cognitive performance. These limitations include; the study population characteristics, nutrients and

doses tested, duration of the study, and the assessment tools of cognitive performance.

Future trials should probably be conducted in patients with (less than) mild cognitive impairment, because the window of opportunity for effective intervention may be as short as 1 year from the onset of medical symptoms, as Martin and colleagues8 suggested. In addition, the duration of administration of the nutrient should be long enough to counteract reversible damage processes to the brain. In designing a trial, researchers should keep in mind which possible nutritional mechanism underlies their study. With respect to the outcome measures, the most ideal situation would be that researchers in the field could use one standard neuropsychological battery of sensitive tests. Comparing studies would thus become easier and more accurate.

The Whitehall-Robins Report is a Wyeth Consumer Healthcare Inc. publication that focuses on current issues on the role of vitamins and minerals in health promotion and disease prevention. Complimentary copies are distributed to Canadian health care professionals active or with a special interest in nutrition. Each issue is written and/or reviewed by independent health care professionals with expertise in the chosen topic.

#### **Editor: Wyeth Consumer Healthcare Inc.**

If you have any comments about the Whitehall-Robins Report or would like to be added to the mailing list, please write to:

The Editor: The Whitehall-Robins Report, 5975 Whittle Road, Mississauga, ON L4Z 3M6

For back issues or further information, visit the Centrum professional section of <a href="https://www.centrumvitamins.ca">www.centrumvitamins.ca</a>.

© 2006 – June. May be reproduced without permission provided source is recognized.

References 1. Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983;249:2917-2921. 2. Riggs KM, Spiro A, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am.J.Clin.Nutr. 1996;63:306-314. 3. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am.J.Clin.Nutr. 2000;71:614S-620S. 4. Gonzalez-Gross M, Marcos A, Pietrzik K. Nutrition and cognitive impairment in the elderly. Br J Nutr 2001;86:313-21. 5. La-Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment [see comments]. Am.J.Clin.Nutr. 1997;65:20-29. 6. Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study [see comments]. Am. J. Clin. Nutr. 2000;71:993-998. 7. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265-1272. 8. Manders M, de Groot LC, van Staveren WA, et al. Effectiveness of nutritional supplements on cognitive functioning in elderly persons: a systematic review. J Gerontol A Biol Sci Med Sci JID - 9502837 2004;59:M1041-M1049. 9. Clarke R, Refsum H, Birks J, et al. Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr 2003;77:1241-7. 10. Clarke R, Grimley EJ, Schneede J, et al. Vitamin B12 and folate deficiency in later life. Age Ageing 2004;33:34-41. 11. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu.Rev.Nutr. 1999;19:357-377. 12. Chanarin I, Deacon R, Lumb M, Perry J. Cobalamin-folate interrelations. Blood Rev 1989;3:211-5. 13. Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. Neurology 1995;45:1435-40. 14. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720-1728. 15. Stabler SP. B12 and nutrition. In: Banjeree R (ed) Chemistry and Biochemistry of B12. New York, 2000. 16. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine Baltimore. 1991;70:229-245. 17. Martin DC, Francis J, Protetch J, Huff FJ. Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. J.Am.Geriatr.Soc. 1992;40:168-172. 18. Hvas AM, Nexo E. Holotranscobalamin-a first choice assay for diagnosing early vitamin B deficiency? J Intern Med 2005;257:289-98. 19. Beck WS. Neuropsychiatric consequences of cobalamin deficiency. Adv Intern Med 1991;36:33-56. 20. Carmel R. Cobalamin, the stomach, and aging. Am J Clin Nutr 1997;66:750-759. 21. Calvaresi E, Bryan J. B vitamins, cognition, and aging: a review. J Gerontol B Psychol Sci Soc Sci 2001;56:327-339. 22. Malouf R, Areosa SA. Vitamin B12 for cognition. Cochrane Database Syst Rev 2003:CD004326. 23. Cunha UG, Rocha FL, Peixoto JM, Motta MF, Barbosa MT. Vitamin B12 deficiency and dementia. Int Psychogeriatr 1995,7:85-8. 24. Teunisse S, Bollen AE, van-Gool WA, Walstra GJ. Dementia and subnormal levels of vitamin B12 effects of replacement therapy on dementia. J. Neurol. 1996;243:522-529. 25. Kwok T, Tang C, Woo J, Lai WK, Law LK, Pang CP. Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int.J.Geriatr.Psychiatry 1998;13:611-616. 26. Eastley R, Wilcock GK, Bucks RS. Vitamin B12 deficiency in dementia and cognitive impairment. the effects of treatment on neuropsychological function. Int.J.Geriatr.Psychiatry 2000;15:226-233. 27. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 2001;16:609-614. 28. van Asselt DZ, Pasman JW, van Lier HJ, et al. Cobalamin supplementation improves cognitive and cerebral function in older, cobalamin-deficient persons. J Gerontol A Biol Sci Med Sci 2001;56:M775-M779. 29. Osimani A, Berger A, Friedman J, Porat-Katz BS, Abarbanel JM. Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects. J Geriatr Psychiatry Neurol 2005;18:33-8. 30. De La Fourniere FFM, Cnockaert X, Chahwakilian A, Hugonot-Diener L, Baumann F, Nedelec C, Buronfosse D, Meignan S, Fauchier C, Attar C, Belmin J, Piette F. Vitamin B12 deficiency and dementia a multicenter epidemiologic and therapeutic study preliminary therapeutic trial. Semaine Des Hopitaux 1997;73:133-40. 31. Seal EC, Metz, L. F, J M. A randomized, double-blind, placebo-controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations. J Am Geriatr Soc, 2002:146-151. 32. Hvas AM, Juul S, Lauritzen L, Nexo E, Ellegaard. No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study. J Affect Disord 2004;81:269-273. 33. Abyad A. Prevalence of Vitamin B12 Deficiency Among Demented Patients and Cognitive Recovery with Cobalamin Replacement. J Nutr Health Aging 2002;6:254-260. 34. Eussen SJPM, de Groot LC, Joosten LWA, et al. Effect of oral vitamin B12 with or without folic acid on cognitive performance in elderly people with mild vitamin B12 deficiency: a randomized, placebo-controlled trial. In press. 35. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. 1988 [classical article]. Nutrition. 1995;11:181. 36. Bell IR, Edman JS, Selhub J, et al. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand 1992;86:386-90. 37. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999;10:12-20. 38. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001;73:927-933. 39. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483. 40. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21-5. 41. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34:1126-9. 42. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003:CD004514. 43. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. Cmaj 2002;166:608-15. 44. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000;35:1305-12. 45. Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 2003,89:483-9. 46. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. Bmj 2002,325,932-3. 47. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005;65:1409-14. 48. Kyle DJ, Schaefer E, Patton G, Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999;34 Suppl:S245. 49. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-6. 50. Heude B, Ducimetiere P, Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA Study. Am J Clin Nutr 2003;77:803-8. 51. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 2000;4:202-7. 52. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr 2003;78:40-6. 53. Lim W, Gammack J, Van Niekerk J, Dangour A. Omega 3 fatty acid for the prevention of dementia. Cochrane Database Syst Rev 2006;CD005379. 54. Stratton RJ. Should food or supplements be used in the community for the treatment of disease-related malnutrition? Proc Nutr Soc 2005;64:325-33. 55. Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2005:CD003288. 56. Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Brain Res Bull 2006;69:1-19. 57. Milne AC, Avenell A, Potter J. Meta-analysis: protein and energy supplementation in older people. Ann Intern Med 2006;144:37-48. 58. Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994;330:1769-75. 59. Hogarth MB, Marshall P, Lovat LB, et al. Nutritional supplementation in elderly medical in-patients: a double-blind placebo-controlled trial. Age Ageing 1996;25:453-7. 60. Lauque S, Arnaud-Battandier F, Mansourian R, et al. Protein-energy oral supplementation in malnourished nursing-home residents. A controlled trial. Age Ageing 2000,29:51-6. 61. van der Wielen RP, van Heereveld HA, de Groot CP, van Staveren WA. Nutritional status of elderly female nursing home residents; the effect of supplementation with a physiological dose of water-soluble vitamins. Eur J Clin Nutr 1995;49:665-74. 62. Faxen-Irving G, Andren-Olsson B, af GA, Basun H, Cederholm T. The effect of nutritional intervention in elderly subjects residing in group-living for the demented. Eur J Clin Nutr JID - 8804070 2002;56:221-227. 63. Wouters-Wesseling W, Wagenaar LW, Rozendaal M, et al. Effect of an enriched drink on cognitive function in frail elderly persons. J Gerontol A Biol Sci Med Sci 2005;60:265-70.

